The U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph ...

demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial ...

If you are unfortunate enough to come down with sickness, Doctor Sooj said: “Stay well hydrated, as this can soothe your ...

The FDA would provide manufacturers with appropriate time to either reformulate drugs containing oral phenylephrine or remove ...

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

Oral phenylephrine, widely marketed in cold and allergy medications, has been in use for decades as a go-to nasal ...

Cold and flu season is upon us and Americans will be flocking to pharmacy shelves to pick up some medicine to alleviate their ...

The FDA announced a proposal to remove oral phenylephrine – a common ingredient in many popular over-the-counter ...

It was added to cold and flu remedies in the 1990s when another ingredient went behind the counter over illicit meth lab concerns.

The FDA proposed discontinuing the use of phenylephrine, an ingredient in common medications like Sudafed, because it 'is not ...

Oral phenylephrine, a common nasal-congestion ingredient in over-the-counter drugs, shouldn't be used in monograph drug products, the Food and Drug Administration is proposing. The agency said a ...

Sinus infections (also known as sinusitis) strike more than 30 million Americans each year. And if you’re one of them, you’re ...